News 2025-02-28
Porton to Showcase Cutting-edge Innovations at BIO-Europe Spring 2025
Porton Pharma Solutions will once again participate
in BIO-Europe Spring 2025, held from March 17th to 19th, at booth #87. This
prestigious event is anticipated to gather over 3,700 scientific leaders and
industry pioneers, fostering new strategic collaborations.
As a globally leading end-to-end CDMO enterprise, Porton Pharma Solutions stands at the forefront of the industry with its cutting-edge technology platforms and extensive project delivery experience. We excel in various fields, including small molecules, peptides and oligonucleotides, antibody-drug conjugates (ADCs) - encompassing antibodies, payload-linkers, conjugation, and formulation filling - as well as Advanced Therapy Medicinal Products (ATMPs).
At this conference, Porton will showcase its latest innovative solutions, aiming to provide you with flexible and diverse collaboration options that cater to your customized needs while driving continuous progress in the biopharmaceutical industry.
We cordially invite you to visit our booth #87 to discuss potential collaboration opportunities.
To ensure a more professional meeting experience for you, we have specially opened a booking channel. To schedule an onsite meeting, please visit our official website's offline meeting page, or directly email us at business@portonpharma.com. Our dedicated team will be more than happy to arrange your meeting and ensure your participation is both efficient and enjoyable.
Join us in exploring the future of pharmaceutical innovation at BIO-Europe Spring 2025!
Others
More
News 2025-03-21
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
News 2025-03-19
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
